DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient
05 Juin 2019 - 7:00AM
DEINOVE & Dow sign a collaboration
agreement for the development of a new cosmetic active
ingredient
- Dow has selected an extract belonging to the DEINOVE
proprietary strains’ bank to launch a new cosmetic active
ingredient for skin care applications
- Commercialization is planned for early 2021
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company that uses a disruptive approach to develop
innovative antibiotics and bio-based active ingredients for
cosmetics and nutrition, announced a collaboration with Dow
(NYSE: DOW) for the joint development of a cosmetic ingredient
derived from its collection of bacterial extracts.
DEINOVE owns a large bacterial collection that
today includes more than 6,000 rare strains, collected in many
different biotopes (hot springs, volcanos, lagoons, beaches,
caves…) and on various substrates (nearly 600 samples of wood,
water, plant, sand,…). DEINOVE has developed original and patented
methods for the selection and culture of these rare bacteria.
Several of these strains have been qualified via DEINOVE’s cell
biology lab according to their properties on different cosmetic
activities (anti-oxidant, anti-inflammatory, cell
regeneration...).
Dow has selected one extract from DEINOVE’s
bacterial bank. DEINOVE will now develop and optimize a dedicated
production process and will ensure the industrial transposition and
production of the developed cosmetic active. Leveraging its
expertise and its cell biology laboratory in Belgium, Dow intends
to qualify the cosmetic active and integrate it into its product
portfolio, receiving commercial exclusivity worldwide.
Fabienne Bizeray, Dow’s Global Strategic
Marketing Leader Skin & Sun Care: "We
have chosen DEINOVE for its widely recognized expertise in
biotechnology and valuation of rare microorganisms. After the
launch of AgeCap Smooth™ in April 2018, this agreement will allow
Dow to quickly develop a new natural cosmetic ingredient for our
customers. This first collaboration with DEINOVE is perfectly
aligned with our strategy of expanding and transforming our
portfolio dedicated to skin care."
"We are proud that a big industrial leader such
as Dow has been convinced by our expertise and attracted by the
richness of our bacterial collection. This agreement values the
quality of our R&D approach and our portfolio of cosmetic
actives.” adds Emmanuel Petiot, CEO of
DEINOVE.
About Dow Home and Personal Care Solutions
Dow Home and Personal Care offers innovative
ingredient solutions that empower brand owners around the world to
create products that meet the needs of today’s consumers. Our
expansive portfolio of chemistries goes into applications across
home and personal care markets, delivering performance and
consumer-desired benefits. We continue to collaborate and innovate
with brand owners, and look ahead of market trends to bring forward
new products that address tomorrow’s challenges like
sustainability, and that differentiate our customers’ products, and
enhance the consumer experience. For more information please visit
consumer.dow.com/personalcare
ABOUT DOW
Dow (NYSE: DOW) combines one of the broadest
technology sets in the industry with asset integration, focused
innovation and global scale to achieve profitable growth and become
the most innovative, customer centric, inclusive and sustainable
materials science company. Dow’s portfolio of performance
materials, industrial intermediates and plastics businesses
delivers a broad range of differentiated science-based products and
solutions for our customers in high-growth segments, such as
packaging, infrastructure and consumer care. Dow operates 113
manufacturing sites in 31 countries and employs approximately
37,000 people. Dow delivered pro forma sales of approximately $50
billion in 2018. References to Dow or the Company mean Dow Inc. and
its subsidiaries. For more information, please visit www.dow.com or
follow @DowNewsroom on Twitter.
CONTACT
Liv
Schneider-AffeldDow Ph.: +34
917407747liv.schneideraffeld@dow.com
ABOUT DEINOVE
DEINOVE is a French biotechnology company, a
leader in disruptive innovation, which aims to help meet the
challenges of antibiotic resistance and the transition to a
sustainable production model for the cosmetics and nutrition
industries.
DEINOVE has developed a unique and comprehensive
expertise in the field of rare bacteria that it can decipher,
culture, and optimize to disclose unsuspected possibilities and
induce them to produce biobased molecules with activities of
interest on an industrial scale. To do so, DEINOVE has been
building and documenting since its creation an unparalleled
biodiversity bank that it exploits thanks to a unique technological
platform in Europe.
DEINOVE is organized around two areas of
expertise:
- ANTIBIOTICS, New-generation anti-infective
agents: DEINOVE is preparing to enter a first antibiotic
candidate into Phase II. The Company is also pursuing the
systematic exploration of biodiversity to supply its portfolio with
new leads, drawing notably on partnerships with Naicons and
bioMérieux (AGIR program supported by Bpifrance).
- BIOACTIVES, Active ingredients of natural
origin with cosmetics as the first market and potential in
nutrition and health: DEINOVE already markets a first innovative
active ingredient, a second in partnership with Greentech, while
two others are in development with Oléos (Hallstar Group). It also
runs a program in animal nutrition with Groupe Avril.
Within the Euromedecine science park located in
Montpellier, DEINOVE employs 62 employees, mainly researchers,
engineers, and technicians, and has filed more than 300 patent
applications internationally. The Company has been listed on
EURONEXT GROWTH® since April 2010.
CONTACTS
Investors
Coralie MartinCommunication,
Marketing and Investor Relations Ph.: +33 (0)4 48 19 01
60coralie.martin@deinove.com
Media
ALIZE
RP
Aurore Gangloff / Catherine Mégélas
Ph.: +33 (0)1 44 54 36 66
deinove@alizerp.com